We have entered a very exciting time in the treatment of advanced ovarian cancer, as our knowledge of the disease and its drivers has evolved significantly. Throughout the past three decades, we have progressed from a “one-size-fits-all” treatment approach to more personalized care based on the biology of each person’s tumor. As a result, targeted treatment options have expanded for women with this challenging disease, which remains the fifth leading cause of cancer deaths among women.
Our recent “Further Than Before” virtual roundtable convened a multidisciplinary panel of some of the top gynecologic oncology experts in the country and a broader care team to discuss the exciting shift to more precise care based on genetic and tumor biomarker testing for ovarian cancer, and why this step is so important for patients with advanced disease.
Tumor biomarker testing has become essential to making informed treatment decisions. In particular, identifying the presence of specific predictive genomic biomarkers associated with homologous recombination deficiency (HRD), which relates to a cell’s inability to repair its own DNA, can affect how the cells in a tumor grow, die and respond to certain treatments. One out of every two women with advanced ovarian cancer has HRD-positive disease, and knowing a woman’s HRD status can help guide treatment approaches, leading to more informed treatment decisions.
Personalized treatment should be standard for all so that no patient is left behind. That is why AstraZeneca is leading the charge to educate oncologists, patients and the full multidisciplinary care team about the importance of HRD testing. If you missed the live session, you can watch the panel discussion highlights video below. Together, we’re forging a new era of precision medicine to bring us closer to achieving our vision of revolutionizing cancer treatment.